ストックスクリーナーアプリを入手
20.97
0.52%
-0.11
プレマーケット:
20.85
-0.12
-0.57%
前日終値:
$21.08
開ける：
$20.98
24時間の取引高:
312.02K
Relative Volume:
0.79
時価総額：
$636.02M
収益：
$344.23M
当期純損益:
$-24.16M
株価収益率:
-24.76
EPS:
-0.8471
ネットキャッシュフロー:
$28.33M
1週間 パフォーマンス:
+4.07%
1か月 パフォーマンス:
-15.48%
6か月 パフォーマンス:
-46.40%
1年 パフォーマンス:
+31.31%
1日の値動き範囲:
$20.45
$21.21
1週間の範囲:
$19.55
$22.18
52週間の値動き範囲:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
名前
Castle Biosciences Inc
セクター
電話
866-788-9007
住所
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
20.97 | 639.36M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
494.04 | 183.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.87 | 129.29B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
566.79 | 44.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.98 | 38.25B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
378.16 | 37.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-04-30 | 開始されました | Lake Street | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | BTIG Research | Buy |
| 2019-08-19 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Castle Biosciences Inc (CSTL) 最新ニュース
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan
Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan
Director at Castle Biosciences (CSTL) granted 11,766 RSUs - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSU compensation award - Stock Titan
Director at Castle Biosciences (CSTL) receives 11,766 RSU equity award - Stock Titan
Castle Biosciences (NASDAQ: CSTL) grants 11,766 RSUs to director - Stock Titan
Is Castle Biosciences Inc (CSTL) a Bargain After 4.7% Drop? GF V - GuruFocus
Castle Biosciences (NASDAQ: CSTL) investors approve directors, pay and KPMG - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Downgraded by Zacks Research to "Hold" - MarketBeat
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN
Castle Biosciences (CSTL) director receives 13,667 shares via RSUs - Stock Titan
Director Daniel Bradbury adds 13,667 CSTL shares via RSU exercise, boosts direct and trust holdings - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into common shares - Stock Titan
Director at Castle Biosciences (CSTL) settles 13,667 RSUs into common stock - Stock Titan
Director at Castle Biosciences (NASDAQ: CSTL) converts 13,667 RSUs to shares - Stock Titan
Director at Castle Biosciences (CSTL) gains 13,667 shares via RSU exercise - Stock Titan
Castle Biosciences (CSTL) director converts 13,667 RSUs into Common Stock - Stock Titan
Castle Biosciences (CSTL) CCO exercises options to add 11,210 shares - Stock Titan
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo Finance
(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Castle Biosciences (CSTL) CEO reports planned stock sales and option exercises - Stock Titan
Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN
Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG - MarketBeat
Portolan Capital amends Castle Biosciences (NASDAQ: CSTL) 13G; 4.45% stake reported - Stock Titan
RTW Funds own 2.76M Castle Biosciences shares (CSTL) — 9.3% stake - Stock Titan
A Look at Castle Biosciences Inc (CSTL) After 4.1% Gain -- GF Va - GuruFocus
Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon - Investing.com
Castle Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-05-13 - Seeking Alpha
META_TITLE_QUOTE - Yahoo Finance
CSTL Maintained by BTIG -- Price Target Lowered to $40.00 - GuruFocus
BTIG lowers Castle Biosciences stock price target on higher costs By Investing.com - Investing.com India
BTIG Research Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - MarketBeat
BTIG lowers Castle Biosciences stock price target on higher costs - Investing.com UK
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference - PR Newswire
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Bre - GuruFocus
Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade - Traders Union
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation - PR Newswire
Price-Driven Insight from (CSTL) for Rule-Based Strategy - Stock Traders Daily
TradingKey - TradingKey
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares By Investing.com - Investing.com Australia
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares - Investing.com India
Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Wall Street Zen - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 145.58% Upside Potential - DirectorsTalk Interviews
CSTL Achieves Strong Q1 Revenue, Raises 2026 Guidance - GuruFocus
CSTL Maintained by Baird -- Price Target Lowered to $43 - GuruFocus
Castle Biosciences Inc (CSTL) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.25%
大文字化:
|
ボリューム (24 時間):